Azmi Yerlikaya, Ph.D.
Affiliations: | 2002 | Pennsylvania State University, State College, PA, United States |
Area:
Animal Physiology Biology, Molecular Biology, BiochemistryGoogle:
"Azmi Yerlikaya"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Anthony E. Pegg | grad student | 2002 | Penn State | |
| (Mechanism of S-adenosylmethionine decarboxylase degradation and changes in substrate S-adenosylmethionine level following inhibition of the 26S proteasome.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Yerlikaya A. (2022) Heme-regulated inhibitor: an overlooked eIF2α kinase in cancer investigations. Medical Oncology (Northwood, London, England). 39: 73 |
| Yerlikaya A, Kanbur E, Stanley BA, et al. (2020) The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer. Anti-Cancer Agents in Medicinal Chemistry |
| Yerlikaya A, Kanbur E. (2020) The ubiquitin-proteasome pathway and resistance mechanisms developed against the proteasomal inhibitors in cancer cells. Current Drug Targets |
| Düzgün ŞA, Yerlikaya A, Zeren S, et al. (2017) Differential effects of p38 MAP kinase inhibitors SB203580 and SB202190 on growth and migration of human MDA-MB-231 cancer cell line. Cytotechnology |
| Yerlikaya A, Erdoğan E, Okur E, et al. (2016) A novel combination treatment for breast cancer cells involving BAPTA-AM and proteasome inhibitor bortezomib. Oncology Letters. 12: 323-330 |
| Yerlikaya A, Erdoğan E, Okur E, et al. (2016) A novel combination treatment for breast cancer cells involving BAPTA-AM and proteasome inhibitor bortezomib Oncology Letters. 12: 323-330 |
| Yerlikaya A, Okur E, Baykal AT, et al. (2015) A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line. Journal of Proteomics. 113: 315-25 |
| Yerlikaya A, Yöntem M. (2013) The significance of ubiquitin proteasome pathway in cancer development. Recent Patents On Anti-Cancer Drug Discovery. 8: 298-309 |
| Yerlikaya A. (2012) Expression of heme oxygenase-1 in response to proteasomal inhibition. Protein and Peptide Letters. 19: 1330-3 |
| Yerlikaya A, Okur E, Ulukaya E. (2012) The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 33: 1385-92 |